Investigational drug · Phase 3
Pembolizumab
Also called: pembro
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Gastric Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M).
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "Pembolizumab"
First trial start
2025
Jun 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pembolizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2-positive Gastric Cancer
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Approved drugs for the same conditions: Stomach and esophageal cancer · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Pembolizumab" as an intervention, largest first.
- A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07332533 · 490 participants (planned) · Start Dec 30, 2025 · Primary completion Jun 30, 2032
Drug: KN026; Capecitabine and 6 more · For: HER2-positive Gastric Cancer
- JSKN003 Combined Treatment of HER2-positive Gastric CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT06998771 · 153 participants (planned) · Start Jun 15, 2025 · Primary completion Jun 30, 2028
Drug: JSKN003; KN026 and 5 more · For: HER2-positive Gastric Cancer
- Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal CancerCompleted
Arrys TherapeuticsIndustry
NCT03658772 · 54 participants · Start Sep 20, 2018 · Primary completion Mar 7, 2023
Drug: grapiprant; grapiprant and pembrolizumab · For: Microsatellite Stable Colorectal Cancer
Sites: Phoenix, Arizona; Aurora, Colorado; Nashville, Tennessee · 4 sites in all
Gruppo Oncologico del Nord-OvestAcademic, hospital or other
NCT07485296 · 45 participants (planned) · Start Jan 27, 2026 · Primary completion Dec 2030
Drug: Pembolizumab · For: Head & Neck Squamous Cell Carcinoma
Sites: Rozzano, Italy
- Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma.Recruiting
Kidney Cancer Research BureauAcademic, hospital or other
NCT07937553 · 40 participants (planned) · Start Aug 15, 2025 · Primary completion Aug 1, 2027
Drug: Lenvatinib; Pembolizumab and 1 more · For: Metastatic Chromophobe Renal Cell Carcinoma
Sites: Chelyabinsk, Russia; Krasnoyarsk, Russia; Orenburg, Russia · 8 sites in all
- NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell CarcinomaStatus unknown
Peter MacCallum Cancer Centre, AustraliaAcademic, hospital or other
NCT05024318 · 20 participants (planned) · Start Feb 8, 2022 · Primary completion Dec 2025
Drug: Pembrolizumab · For: Renal Cell Carcinoma, Clear Cell, Somatic
Sites: Woolloongabba, Australia; Melbourne, Australia
- A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck CancerNot yet recruiting
Glycyx TherapeuticsIndustry
NCT07662720 · 18 participants (planned) · Start Jul 15, 2026 · Primary completion Aug 31, 2027
Drug: axelopran; Pembolizumab · For: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
John MascarenhasAcademic, hospital or other
NCT03065400 · 10 participants · Start Jun 14, 2017 · Primary completion May 28, 2020
Drug: Pembrolizumab · For: Chronic Phase Myelofibrosis; Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis and 1 more
Sites: Boston, Massachusetts; New York, New York; The Bronx, New York
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05879120 · 0 participants · Start Jul 30, 2024 · Primary completion Oct 2, 2024
Drug: Pembrolizumab · For: Recurrent Glioblastoma
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Circulating Tumor DNA Clearance Is Associated with Response and Survival in Metastatic Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin Plus Pembrolizumab.
Khorasanchi A, Mullick Chowdhury S, Hong EF, et al. · Cancers (Basel) 2026
- Changes in Treatment Patterns and Survival Outcomes Across Therapeutic Eras in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study.
Tomioka S, Inoue S, Kawase R, et al. · Int J Urol 2026
- Descriptive analysis of the use of pembrolizumab in combination with lenvatinib in the treatment of endometrial cancer in four university hospitals in Quebec, Canada.
Guévremont C, Simard M, Fortier S, et al. · Eur J Obstet Gynecol Reprod Biol 2026
- A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.
Hatoum F, Dyer B, Heiligh J, et al. · Future Oncol 2026
- Occult breast cancer showing a marked response to pembrolizumab plus gemcitabine and carboplatin therapy complicated by immune-related colitis: A case report.
Inohana W, Ohara M, Mikami E, et al. · Mol Clin Oncol 2026
- Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Kamada R, Yokouchi H, Mizobuchi S, et al. · Thorac Cancer 2026
Also in development for HER2-positive Gastric Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- JSKN003Phase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer
- KN026PlacboPhase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer
- HLX22Phase 34 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer, HER2-low Hormone Receptor Positive Breast Cancer, Gastroesophageal-junction Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.